Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07180992

Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma

Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation. Monocytosis and monocytes typing are described in multiple myeloma response as factors on proliferation and cell death evasion. CART cells have improved multiple myeloma care in last 5 years, nethertheless, early relapse occur and we must identify predictor factors of better response. The aim of this study is to analyze basic level and phenotyping of monocytes before and after CART cells infusion and study their impact on multiple myeloma response

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Myeloma Blood Protein Disorders CART Cells Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Monocytes Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU Amiens

Amiens, France

Location status: Recruiting

Location contact

Lydia Montes, MD

CONTACT

[email protected]

33+322088371

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 18 years old
  • Treated for a multiple myeloma
  • CART cells treatment proposed
  • Affiliated to social security system
  • Agreed to participate to the study

Treatment and study plan

Primary outcomes

  1. overall response rate

    Time frame: day 1

Secondary outcomes

  1. Progression free survival

    Time frame: 3 years

  2. Overall survival

    Time frame: 3 years

  3. time to next treatment

    Time frame: 3 years

Study contacts

Contact information is provided by the study sponsor or research team.

Lydia Montes, MD

CONTACT

[email protected]

33+322088371

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: MONOMM

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Sep 18, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.